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SUMMARY
Male osteoporosis is now a well-recognized medical disorder with established clinical guidelines for both diagnosis and manage-
ment. Prevention as well as management of osteoporosis in men consulting the andrological outpatient clinic because of low testos-
terone, however, is not well established. This gap of knowledge is—at least partly—explained by the controversy with respect to the
threshold of testosterone needed for skeletal maintenance. However, testosterone deficiency may be clearly associated with bone
loss as well as frailty in men. If anything, andrologists should therefore be aware of the potential silent presence of osteoporosis in
men with confirmed hypogonadism. Therefore, the management of patients with potential hypogonadism should include a com-
plete bone health assessment, besides clinical and biochemical evaluation of gonadal status. Such bone health assessment should
include specific items in medical history and physical examination related to fracture risk. Furthermore, dual-energy absorptiometry
is indicated to evaluate fracture risk in men with confirmed clinical hypogonadism. Regarding treatment, besides general measures
to prevent or manage male osteoporosis testosterone replacement can be initiated (as described in guidelines for hypogonadism),
but data on its efficacy in preventing fractures are lacking. Thus, additional anti-osteoporotic may be needed, especially in men with
very low testosterone who are at high risk of bone loss and/or in men not able to receive testosterone replacement.
INTRODUCTION
Osteoporosis is an important health problem not only in women
but also in men. Hypogonadism is a well-established cause of sec-
ondary osteoporosis in men. Both primary hypogonadism and
secondary hypogonadism are associated with low bone density
(Khosla et al., 1998; Fink et al., 2006; Rochira et al., 2006, 2015).
Increase in fracture risk is, however, only well documented in
patients following androgen deprivation therapy (ADT: surgical or
chemical castration in prostate cancer patients or hypersexuality)
(Shahinian et al., 2005). Indeed, ADT is associated with rapid bone
loss (Stepan et al., 1989) as well as subsequent bone fragility (Sha-
hinian et al., 2005; Wang et al., 2015; Wu et al., 2015).
Moreover, testosterone prevents bone loss in hypogonadal
men (Amory et al., 2004), especially in men with low testos-
terone concentrations (<200 ng/dL) (Snyder et al., 1999, 2017).
In men with borderline low or low normal testosterone levels
however, such as in some patients with Klinefelter syndrome,
bone density may be preserved also without testosterone
replacement (Bonomi et al., 2016).
Although male osteoporosis is now a well-recognized clinical
entity, it remains an underdiagnosed and undermanaged condi-
tion (Madeo et al., 2007; Willson et al., 2015). Although several
general guidelines for the management of osteoporosis contain
advice concerning male osteoporosis (Appendix 1), only a few
guidelines specific for male osteoporosis have been released. No
specific guidelines on hypogonadal osteoporosis are however
available.
For this reason, this manuscript presents a more practical
approach for the assessment and management of bone health in
patients consulting an andrological outpatient clinic, including
both prevention and management of osteoporosis in hypogo-
nadal men.
To enhance the value of the clinical advice here provided,
we used the GRADE (Grading of Recommendations,
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Assessment, Development, and Evaluation) system for grading
the quality of evidence and the strength of recommendations
(Swiglo et al., 2008). The GRADE system is a method of devel-
oping evidence-based guidelines involving key recommenda-
tions and the use of a consistent language and graphical
descriptions for standardizing the grading of both the strength
of recommendation and the quality of evidence (Swiglo et al.,
2008) (17, 20). The number 1 indicates a strong recommenda-
tion and is associated with the terminology ‘we recommend’;
the number 2 denotes a weak recommendation and is associ-
ated with the wording ‘we suggest’. The grading of the quality
of evidence employs the following graphical descriptions:
⊕○○○ denotes very low-quality evidence; ⊕⊕○○, low quality;
⊕⊕⊕○, moderate quality; and ⊕⊕⊕⊕, high quality (Swiglo
et al., 2008). In addition, we provide three clinical vignettes
that summarize different scenarios common in andrological
patient practice (Boxes 1–3).
APPROACHING BONE HEALTH IN THE PATIENT WITH
HYPOGONADISM
Low circulating sex steroids (both androgens and estrogens)
are associated with reduced bone mineral density (BMD) in men
of any age (Khosla et al., 1998; Fink et al., 2006; Rochira et al.,
2006, 2015), and this association is supported by clear patho-
physiological evidence (Almeida et al., 2017). Bone health
assessment is therefore needed in men with confirmed
hypogonadism.
Clinical evaluation: the role of patient’s medical history and
physical examination
Both medical history and appearance at physical examination
(Table 1) might prompt further investigation in hypogonadal
patients. Further clinical workup should be addressed to (i) diag-
nose osteopenia/osteoporosis, (ii) assess fracture risk and/or
concomitant presence of fractures, and finally (iii) establish ther-
apeutic strategies (Watts et al., 2012; Vescini et al., 2016).
A detailed patient’s interview should be considered prior to
proceed to a complete bone workup (Lewiecki, 2015). Further
examinations are needed if one or more of the aspects listed in
Table 1 are present. Furthermore, risk factors for osteoporosis
and fractures related to lifestyle, other treatments, and related
diseases (Table 2) should be addressed (Kanis et al., 2005a,b; de
Kam et al., 2009; Drake et al., 2012; Lewiecki, 2015). In particu-
lar, alcohol intake should be evaluated as alcohol abuse is an
important cause of male osteoporosis. Smoking and excessive
alcohol consumption (daily intake or ≥10 units per week or ≥3
units/day) are major risk factors for osteoporotic fractures in
men (Kanis et al., 2005a,b; Drake et al., 2012).
Information on current or past glucocorticoid treatment
should be obtained as glucocorticoid treatment is a strong risk
factor for both osteoporosis and osteoporotic fractures (Drake
et al., 2012).
Physical examination
Statements
• We recommend considering bone health in all andrological
patients with documented hypogonadism at first visit. 1|
⊕⊕○○
• We suggest assessing clinical aspects of bone health as
reported in Table 1. 2|⊕⊕○○
• We suggest including spine observation and follow-up of
patient’s height in the clinical workup. 2|⊕⊕○○
Evidence
Silent spine fractures may also occur in men similar to women
and are an important first sign of osteoporosis (Lewiecki, 2015).
Decrease in height, the presence of dorsal kyphosis, a wall-to-
occiput distance >0 cm, and a rib-to-pelvis distance <2 fingers
might suggest the presence of occult vertebral fractures in men
(Table 1) (Green et al., 2004). Wall-to-occiput distance is easily
obtained by placing the patient against the wall and measuring
the distance between the wall and the occiput (Green et al., 2004).
Biochemical evaluation: the role of sex steroid measurements
Statements
• We recommend having serum total testosterone measured
twice on a morning blood sample. 1|⊕⊕⊕○
• We recommend measuring again total testosterone and SHBG
if only a single measurement documenting low testosterone is
available. LH and prolactin are useful to better characterize
hypogonadism. 1|⊕⊕⊕○
• We do not recommend routine measurement of serum estra-
diol. 1|⊕⊕○○
• We suggest measuring estradiol only when a validated mass
spectrometry-based method is available and in rare cases in
which severe estrogen deficiency is suspected. 2|⊕⊕○○
Evidence
It is well established that circulating sex steroids should be in
the male normal range to ensure bone health (Rochira et al.,
2006; Almeida et al., 2017). For this reason, all patients with doc-
umented low serum testosterone consulting with hypogonadal
symptoms should receive a biochemical evaluation of their
gonadal status, with measurement of serum total testosterone,
SHBG, luteinizing hormone (LH), follicle-stimulating hormone
(FSH), and prolactin (Wang et al., 2009; Bhasin et al., 2010;
Buvat et al., 2013; Huhtaniemi, 2014; Lunenfeld et al., 2015).
Gonadotropins are needed to differentiate primary hypogo-
nadism from secondary hypogonadism, whereas normal pro-
lactin levels allow excluding hyperprolactinemia as the cause of
hypogonadism (Basaria, 2014).
Serum testosterone
Hypogonadism should be confirmed twice on a morning
blood sample (Wang et al., 2009; Bhasin et al., 2010; Buvat
et al., 2013; Basaria, 2014; Huhtaniemi, 2014; Lunenfeld et al.,
2015). The threshold of serum total testosterone for skeletal
maintenance is not well defined (Finkelstein et al., 2016).
Some indirect evidence, however, suggests that a threshold
below 200 ng/dL may be used (Snyder et al., 1999; Finkelstein
et al., 2016).
When serum total testosterone is between 200 and 300 ng/dL,
the presence of hypogonadal symptoms may help in confirming
the diagnosis and other aspects (e.g., patients’ age, obesity) are
determinant for clinical relevance of low serum testosterone
(e.g., vignette 3; Box 3).
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Severe hypogonadism and mild hypogonadism have a differ-
ent impact on bone mass than slightly low serum testosterone
(in-between 200 and 300 ng/dL). Severe hypogonadism (serum
total testosterone <100 ng/dL) may lead to bone loss and often
osteoporosis, independently from the patient’s age as illustrated
in the clinical vignette 1 (Box 1). In case of severe hypogo-
nadism, concomitant osteoporotic fractures (commonly of the
spine) might be present at the diagnosis both in young and older
men as in clinical vignette 1 (Box 1) and 2 (Box 2), respectively.
Conversely, a clear cause–effect relationship between bone and
gonadal status remains weak in case of mild to slight hypogo-
nadism depicted by clinical vignette 3 (Box 3). These different
phenotypes of male hypogonadism may therefore have different
impact with respect to diagnosis and management of bone
health.
Serum estradiol
Serum estradiol is an important determinant of bone mass in
men (Rochira et al., 2015; Almeida et al., 2017), and bone loss in
hypogonadal men may also be related to estrogen deficiency
(Rochira et al., 2006; Finkelstein et al., 2016). Accordingly,
hypogonadal men without relative estrogen deficiency have
higher BMD than those with both low testosterone and estradiol
(Aguirre et al., 2015). Theoretically, serum estradiol may be a
good marker to identify hypogonadal men with a worse bone sta-
tus, but the role of estradiol measurement for the diagnosis and
management of hypogonadal osteoporosis is currently not well
established, in part due to pitfalls related to the measurement of
estradiol in the low male normal range (Rochira et al., 2015,
2016). Estradiol becomes important in hypogonadal osteoporosis
only when severe estrogen deficiency is suspected (Rochira & Car-
ani, 2009).
Remarks
Serum total testosterone can be assayed by commercially
available kits or using the gold standard represented by liquid
chromatography–tandem mass spectrometry (LC-MS/MS),
which is becoming more and more available in the clinical set-
ting (Simoni et al., 2012).
We suggest using calculated free testosterone when needed,
based on the measurement of total serum testosterone, SHBG,
and albumin (Vermeulen et al., 1999). It can easily be obtained
using online available calculators (see Appendix 2 for Web links).
Commercially available kits for direct measurement of free
testosterone should not be used due to their poor accuracy and
reliability (Rosner et al., 2007; Bhasin et al., 2010).
Commercially available kits for the measurement of serum
estradiol have poor accuracy and are not reliable for the measure-
ment of estradiol within the low male normal range (Rosner et al.,
2013; Demers et al., 2015), the finding of elevated or normal to
high serum estradiol being useful only to rule out relative estrogen
deficiency in men with low testosterone (Finkelstein et al., 2016;
Rochira & Carani, 2017). However, even when performed with
accurate and precise techniques such as LC-MS/MS, the clinical
use of serum estradiol remains not validated (Demers et al.,
2015). Thus, at present, the measurement of serum estradiol is
not useful in routine clinical practice (Demers et al., 2015).
Biochemical evaluation: other biochemical measurements
Statements
• We suggest measuring serum 25(OH) vitamin D at baseline in
all hypogonadal men, independently from their BMD. 2|⊕⊕○○
• We suggest measuring serum calcium (or calcium corrected
for albumin when it is applied—see Appendix 2 for Web
links), phosphorous, and PTH in all hypogonadal patients
with documented low BMD. 2|⊕⊕○○
• We do not recommend the routine use of bone turnover
markers in the management of male or hypogonadal osteo-
porosis. 1|⊕⊕⊕○
Vitamin D, calcium, PTH
Vitamin D deficiency may be more prevalent in hypogonadal
men (Lee et al., 2012). Although low testosterone may also con-
tribute to lowering circulating active forms of vitamin D (Ferlin
et al., 2013), serum 25(OH) vitamin D should be used as the mar-
ker of vitamin D deficiency (Swanson et al., 2014). However,
measuring 25(OH) vitamin D levels can be technically challeng-
ing and a properly validated assay should be used (Bouillon
et al., 2013). For vitamin D, a 25(OH) vitamin D serum level of
Box 1
Clinical vignette 1 depicting a standard case of an adult male patient with
severe hypogonadism and severe osteoporosis characterized by multiple
vertebral fractures at the time of the diagnosis.
Clinical Vignette 1
Patient: 40 year old man
Past history: delayed puberty, one-year treatment with gonadotropins for
hypogonadotropic hypogonadism at the age of 18 years, subsequent long-
term period without androgen replacement treatment, heavy smoker
Reasons for andrological consultation: signs (eunuchoid habitus,
incomplete pubertal development, reduced body hair) and symptoms
(anosmia) of hypogonadism (other: low libido, low volume of ejaculate, and
erectile dysfunction)
Physical examination: dorsal kyphosis, eunuchoid skeletal proportions
Hormones: Low to suppressed LH and FSH, serum T: 73 ng/dL (normal
range: 300–900 ng/dL), normal serum prolactin, and vitamin D
DXA: lumbar T-score: 2.2; femoral T-score: 2.4 (lumbar and femoral
osteopenia).
FRAX: 18% risk of major osteoporotic fractures: 13% risk of hip fracture
X-ray of the spine: showed wedge (grade 1) vertebral fractures of T9, T10,
and T11 vertebrae.
Diagnosis: severe hypogonadotropic hypogonadism due to Kallmann
syndrome associated with severe osteoporosis
Proposed treatment: should receive TRT or gonadotropin treatment if
fertility is requested
Summary of relevant aspects
This clinical vignette highlights that:
○ BMD measurement alone may not be sufficient for a complete diagnosis
○ Osteoporotic, atraumatic fractures may appear early in life in case of severe
male hypogonadism, especially if untreated
○ Physical examination is useful in suggesting further radiological examination
that might change the diagnosis of osteoporosis
Practical tools:
○ Check occult fractures in male patients with hypogonadism, especially in severe
hypogonadism
○ Obtain FRAX score for assessing fracture risk
○ Young adults with osteoporosis and severe hypogonadism are good candidates
for TRT
○ Occult osteoporotic fractures need also specific antiresorptive treatment
TRT, testosterone replacement treatment.
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20 ng/mL (50 nmol/L) is generally accepted as sufficient for
bone health (Bouillon et al., 2013).
Serum calcium, phosphorous, and parathyroid hormone
(PTH) measurement should rule out other prevalent forms of
secondary osteoporosis (or osteopenia) such as primary hyper-
parathyroidism (Marcocci & Cetani, 2011; Bilezikian et al., 2014;
Khan et al., 2016) (Table 2).
Bone turnover markers
The role of serum bone turnover markers such as bone-speci-
fic alkaline phosphatase, osteocalcin, urinary collagen type 1
cross-linked N-telopeptide (NTX), and collagen type 1 cross-
linked C-telopeptide (CTX) in the workup of hypogonadal osteo-
porosis is not well established. High bone turnover markers in
hypogonadal men may however reflect high bone turnover and
therefore ongoing bone loss. At present, there is also no evidence
about the value of bone turnover markers for either determina-
tion of fracture risk or selection of patients who need to be trea-
ted (Vasikaran & Chubb, 2016). Antiresorptive treatment may
however reduce bone turnover markers in hypogonadal
osteoporosis (Vasikaran & Chubb, 2016), but their use in follow-
up of treatment is not well validated.
Diagnosis: the role of bone imaging
As male hypogonadism may cause osteoporosis, all andrologi-
cal patients with confirmed hypogonadism should undergo fur-
ther evaluation of bone density. Bone imaging, by the use of
DXA and plain x-ray, aims to (i) ascertain whether osteopenia or
osteoporosis is present; (ii) diagnose previous or concomitant
osteoporotic fractures (often overlooked or underestimated in
men); and (iii) prevent future fractures.
The role of DXA in the evaluation of bone status
Statements
• We recommend BMD measurement by DXA in all hypogo-
nadal patients with documented hypogonadism and/or
serum testosterone <200 ng/dL. 1|⊕⊕⊕○
• We suggest BMD measurement by DXA in all hypogonadal
patients with slightly decreased serum total testosterone (be-
tween 200 and 300 ng/dL), especially in young patients or in
patients with hypogonadal symptoms. 2|⊕⊕○○
• We recommend that all patients who need ADT (for prostate
cancer or hypersexuality) should also be evaluated by DXA.
1|⊕⊕⊕⊕
• We suggest BMD measurement by DXA in men with a well-
documented history of hypogonadism. 2|⊕⊕⊕○
Table 1 Main aspects to be considered during first visit
Aspects to be considered at medical interview
Major aspects
Long-term severe androgen deprivation at any age (not treated congenital
hypogonadism, castration, drugs)
Bone pain, especially back pain
Concomitant diseases strictly associated with male osteoporosis: HIV/COPD/
thalassemia/viral hepatitis
Medications (e.g., glucocorticoids)
Decrease in stature (height loss), especially in older men
Osteoporosis and/or osteoporotic fractures among relatives
History of prior atraumatic or low trauma fractures
Tendency to fall, especially in older men
Minor aspects
Physical performance changes
Lifestyle (Alcohol and smoking)
Intestinal transit
Aspects to be considered at physical examination
Major aspects
Height measurement
Presence of kyphosis
Wall-to-occiput distance >0 cm
Body composition/muscle masses
Testes volume
Minor aspects
Rib-to-pelvis distance <3 fingers
Eunuchoid body proportions
Humpback
Weight
Tooth loss
Blue sclera, especially in young patients
ADT, androgen deprivation therapy; HIV, human immunodeficiency virus infec-
tion; COPD, chronic obstructive pulmonary disease.
Box 2
Clinical vignette 2 depicting a standard case of an older man with severe
hypogonadism and concomitant severe osteoporosis with multiple vertebral
fractures.
Clinical Vignette 2
Patient: 70 year old man
Past history: diagnosis of isolated hypogonadotropic hypogonadism
treated since the age of 30 years. No TRT treatment during the last 40 years
Reasons for andrological consultation: hospitalization for fatigue, slight
degree of sarcopenia, and diffuse bone pain (particularly back pain)
Physical examination: undervirilization, dorsal kyphosis, eunuchoid
skeletal proportions, bilateral valgism, and bilateral gynecomastia, 2.5 cm
reduction in height during the last 3 years
Hormones: Low to suppressed LH and FSH, serum T: 130 ng/dL (normal
range: 300–900 ng/dL), normal serum prolactin, 25(OH) vitamin D:
17.1 ng/mL (normal range: 30–100 ng/mL)
DXA: lumbar T-score: 4.0 (z-score: 3.1); femoral T-score: 3.4
FRAX: 22% risk of major osteoporotic fractures: 11% risk of hip fracture
X-ray of the spine: reduction in height of the vertebral body of D6, D7,
D9, D10, D11, and L4 vertebrae together with a fracture of the sixth right rib
Diagnosis: severe hypogonadotropic hypogonadism associated with severe
osteoporosis
Proposed treatment: should restart TRT treatment and receive also anti-
osteoporotic treatment with proven antifracture efficacy
Summary of relevant aspects
This clinical vignette highlights that:
○ Even when indicated, TRT treatment in older patients might be discontinued due
to several reasons: lack of compliance, frailty and poor health conditions, and
contraindications that are frequent in the elderly (e.g., increased hematocrit,
suspected or diagnosed prostate cancer, severe chronic coronary disease)
○ The best option is to add antiresorptive or anabolic bone treatment to TRT
(combined therapy) as TRT alone is not sufficient to guarantee bone health.
○ In case of contraindications to TRT administration, antiresorptive or anabolic
bone treatment alone should be administered to treat osteoporosis.
○ Vitamin D deficiency should be corrected
Practical tools:
○ Focus mainly on prevention of further fracture (specific treatment for osteoporosis)
rather than on hypogonadism and prevention of bone loss with TRT
○ Severe osteoporosis in older patients needs prevention of falls, especially in case of
sarcopenia
TRT, testosterone replacement treatment.
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Evidence
In clinical practice, dual-energy X-ray absorptiometry (DXA) is
the best diagnostic tool to assess BMD in hypogonadal men,
whereas pQCT and bone ultrasound only have a role in research
or screening (Lewiecki, 2013).
All patients with documented or previous history of hypog-
onadism should undergo DXA analysis at both lumbar and
femoral site (Watts et al., 2012). Even patient’s documented
hypogonadism in the past might have caused bone loss,
especially if occurred during puberty or early adult life
(Finkelstein et al., 1987; Soyka et al., 2000). In the andrologi-
cal setting, DXA provides information about baseline bone
status as well as on the patient’s risk of future osteoporotic
fractures. BMD as assessed by DXA, in fact, correlates with
fracture risk at all sites in men (Cummings et al., 2006; Lewis
et al., 2007) when measured at lumbar and femoral sites
(Yang et al., 2012). The association between low BMD and
fracture is therefore also valid in hypogonadal patients (Gaff-
ney et al., 2015) and especially patients undergoing androgen
deprivation (Wadhwa et al., 2009). In particular, future bone
loss is also strongly associated with osteoporotic fractures
(Cawthon et al., 2012).
According to the WHO criteria, in men a T-score equal or
<2.5 is used for the clinical diagnosis of osteoporosis, and a
T-score between 1.0 and 2.5 indicates low bone mass (os-
teopenia) (Kanis et al., 1994). The diagnosis of severe osteoporo-
sis occurs also when a fragility fracture is documented (Kanis
et al., 1994).
Remarks
The WHO criteria for the diagnosis of osteoporosis in men are
still controversial (Binkley et al., 2014). The site of BMD measure-
ment (lumbar vs. femoral), the use of different T-scores coming
from different populations (male vs. female), and how to consider
a given T-score in relation to a patient’s age (young vs. older men)
are the main controversial issues (Binkley et al., 2014).
A T-score equal or <2.5 at the femoral neck is considered as
the reference standard in men by the WHO Collaborating Cen-
tre, the International Osteoporosis Foundation (IOF) (Kanis
et al., 2008, 2011), and the UK National Osteoporosis Guideline
Group (NOGG) (Compston et al., 2013).
The recommended site of DXA measurement differs across
various guidelines: hip and spine by the US National Osteoporo-
sis Foundation and the Endocrine Society (Watts et al., 2012),
and the lowest T-score value for the BMD measured at the lum-
bar spine, total hip, or femoral neck by the Osteoporosis Canada
(Papaioannou et al., 2010).
As far as the population used for the T-score is concerned, the
Endocrine Society recommends using male reference data
(Watts et al., 2012), the International Society of Clinical Densito-
metry recommends the female standards for calculating male
T-scores (Watts et al., 2013), while the WHO, IOF, and Scientific
Advisory Council of Osteoporosis Canada recommend the use of
the reference database at the femoral neck of Third National
Health and Nutrition Examination Survey (NHANES III)
obtained from young women (20–29 years old) (Kanis et al.,
2008; Papaioannou et al., 2010).
In guidelines of male osteoporosis, DXA is mostly indicated
after age 50 (Watts et al., 2012). However, in young patients with
confirmed hypogonadism, it may be important to have a DXA at
start of TRT to be able to follow up evolution at later stages
(Kanis et al., 2011). For instance, if patients interrupt their TRT,
Table 2 Risk factors for male osteoporosis. Risk factors that are of particular
importance in men are reported in bold
Risk factors for osteoporosis
Lifestyle
Alcohol intake/sedentary lifestyle/smoking/undernutrition
Medications
Glucocorticoids/ADT/anticonvulsants/chemotherapeutics
Other endocrine diseases
Delayed puberty/hypogonadism/acromegaly/Cushing syndrome/
hyperparathyroidism/hyperthyroidism/diabetes mellitus
Other diseases
Gastrointestinal malabsorption (e.g., celiac disease, bariatric surgery)/
rheumatoid arthritis/chronic kidney disease/HIVa/COPD/neoplastic
diseases/iron overload (thalassemia, hemochromatosis)/idiopathic
hypercalciuria/osteogenesis imperfecta/neuromuscular diseases/
multiple myeloma
ADT, androgen deprivation therapy; HIV, human immunodeficiency virus infec-
tion; COPD, chronic obstructive pulmonary disease. aOsteoporosis is more preva-
lent in men than in women with HIV.
Box 3
Clinical vignette 3 depicting a standard case of an adult man with borderline
serum total testosterone and osteopenia.
Clinical Vignette 3
Patient: 54 year old man
Past medical history:metabolic syndrome since the age of 48, heavy
smoker
Reasons for andrological consultation: loss of libido, slight erectile
dysfunction
Physical examination: overweight (BMI: 29; normal <25) and visceral
obesity (waist circumference: 104 cm; normal <94 cm)
Hormones: Normal LH and FSH, serum T: 270 ng/dL (normal range: 300–
900 ng/dL), normal serum prolactin, serum estradiol in the highest quartile
of the normal range, 25(OH) vitamin D: 12 ng/mL (normal range: 30–
100 ng/mL).
DXA: lumbar T-score: 1.8; femoral T-score: 1.9
FRAX: 5.9% risk of major osteoporotic fractures: 2.2% risk of hip fracture
Diagnosis: slight hypogonadism and osteopenia
Proposed treatment: no need for anti-osteoporotic treatment
Summary of relevant aspects
This clinical vignette highlights that:
○ Slightly reduced borderline serum testosterone has little impact on bone loss
○ Overweight and obese men with hypogonadism have a reduced risk of
osteoporosis thanks to increased aromatization and protective estrogen effect
○ Borderline serum testosterone usually does not require additional radiological
examinations other than DXA
○ Check vitamin D and replace if deficient
Practical tools:
○ BMD and fracture risk are not significantly modified by small decrease in
serum testosterone
○ Slight hypogonadism does not necessarily need TRT
○ Wait-and-see approach preferred
○ Diet, physical exercise, and other lifestyle changes as first-line therapy
○ Treat with TRT if both BMD and serum testosterone decline during follow-up
○ TRT might help preventing further bone loss and the development of overt
osteoporosis
TRT, testosterone replacement treatment.
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DXA may decrease rapidly and give the andrologist an important
indication about compliance.
The role of X-ray in the detection of vertebral fractures
Statements
• We recommend X-ray of the dorsolumbar spine when osteo-
porotic fractures are suspected on the basis of patient’s medi-
cal history, physical examination, and/or the presence of
localized bone pain. 1|⊕⊕⊕○
• We recommend using X-ray to confirm the diagnosis of severe
osteoporosis. 1|⊕⊕○○
• We however do not recommend the use of X-ray for the diag-
nosis of osteoporosis or osteopenia. 1|⊕⊕⊕⊕
Evidence
X-ray is the best diagnostic tool to identify vertebral fractures
as first-line examination. Spine fractures in men as well as in
women occur at the distal thoracic and upper lumbar spine. CT
scan and MRI may confirm the diagnosis but are rarely needed
(Lewiecki, 2013). X-rays are easy to perform, not expensive,
available worldwide also in basic clinical setting, and are very
sensitive for the detection of fractures (especially vertebral
fractures) (see Appendix 2 for Web links to the Genant
classification).
The role of other imaging techniques
Statements
• We do not recommend the use of other different techniques
than DXA and X-ray for the diagnosis of osteoporosis or
osteopenia and osteoporotic fractures. 1|⊕⊕⊕○
Evidence
Although QCT shows a disturbed microarchitecture and bone
density assessed by ultrasound is also lower in hypogonadal
men (Tajar et al., 2012; Finkelstein et al., 2016), these techniques
are less well-established markers of fracture risk (Lewiecki,
2013).
Fracture risk assessment
Statements
• We suggest calculating the FRAX score in all men with con-
firmed hypogonadism. 2|⊕⊕⊕○
Evidence
BMD measurement represents a surrogate marker of fracture
risk as low BMD is associated with an increased risk of fractures
at all sites in men (Pasco et al., 2014).
The Fracture Risk Assessment Tool (FRAX) (see Appendix 2
for Web links) is also of value in predicting fracture risk in men
(Harvey et al., 2016) with or without BMD value (Ettinger et al.,
2013). It is not time-consuming and therefore could be easily
used in hypogonadal patients. The score obtained allows an esti-
mation of future osteoporotic fractures and hereby might help to
decide whether or not additional anti-osteoporotic treatment is
needed (Cosman et al., 2014).
Remarks
It has been suggested that a 10-year risk of hip fracture greater
than or equal to 3% (obtained by FRAX) in men older than
50 years with low bone mass (osteopenia or osteoporosis) at
femoral neck, total hip, or lumbar spine by DXA should be con-
sidered as a possible threshold for starting a treatment for osteo-
porosis (Cosman et al., 2014).
It has been suggested that a 10-year risk of major osteoporotic
fractures greater than or equal to 20% (obtained by FRAX) in
men older than 50 years with low bone mass (osteopenia or
osteoporosis) at femoral neck, total hip, or lumbar spine by DXA
should be considered as a possible threshold for starting a treat-
ment for osteoporosis (Cosman et al., 2014).
No evidence exists to propose treatment thresholds based on
FRAX score in men younger than 50 years.
Treatment
The main goal of treating hypogonadal men with osteo-
porosis is to decrease the risk of osteoporotic fractures. How-
ever, most studies in men have addressed only surrogate
endpoints such as BMD, but not fracture endpoints. Further-
more, the data available from the trials investigating the effi-
cacy of anti-osteoporotic drugs for the treatment of
osteoporosis represent an additional limitation as the number
of men enrolled in those studies is much smaller compared
to the female participants.
Lifestyle factors
Statements
• In general, smoking cessation, a reduction in alcohol intake,
and weight-bearing exercises are recommended. 1|⊕⊕○○
• We suggest introducing lifestyle interventions when hypogo-
nadism is diagnosed or when ADT is started and should be
continued throughout life. 2|⊕⊕○○
Evidence
Lifestyle interventions are recommended in all men at risk of
osteoporosis and therefore also in all hypogonadal men (Pye et al.,
2010). Smoking cessation and alcohol abstention are needed for
heavy smokers or alcoholics, and in general, reduction in smoking
and in alcohol intake is advisable (Vescini et al., 2016). Further-
more, increasing physical activity can have a positive effect on
BMD and may reduce the risk of falls and fall-related fractures (de
Kam et al., 2009). In addition, weight loss in obese subjects might,
in part, increase serum testosterone (Corona et al., 2013).
Calcium and vitamin D supplementation
Statements
• We suggest increasing dietary intake of calcium if the dietary
calcium intake is insufficient. 2|⊕⊕○○
• If dietary calcium intake remains inadequate and/or
vitamin D serum levels are low, we suggest initiating phar-
macological supplementation with both calcium and
vitamin D. 2|⊕○○○
• We do not recommend monotherapy with either one of them.
1|⊕⊕○○
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• We do not recommend the use of calcium/vitamin D supple-
mentation as the only treatment for hypogonadal osteoporo-
sis or androgen deprivation therapy-associated bone loss.
1|⊕⊕⊕○
• We recommend starting antiresorptive therapy only in combi-
nation with calcium and vitamin D supplementation.
1|⊕⊕○○
Evidence
Both calcium and vitamin D are important for bone health. An
average daily intake of 1000–1200 mg of calcium and 800 units
of vitamin D is generally recommended, ideally via dietary intake
(Bouillon et al., 2013). Daily dietary calcium intake can be esti-
mated via a dietary history (see Appendix 2 for Web links).
Remarks
Men with malabsorption (for instance, after bariatric surgery)
or low sunlight exposure (institutionalized patients) are at
increased risk of vitamin D deficiency.
Monotherapy with either calcium or vitamin D, however, has
not proven to increase BMD or decrease fracture risk (Bouillon
et al., 2013; Avenell et al., 2014; Reid et al., 2014).
Compliance and continuation of treatment with calcium/vita-
min D are important. BMD increases are lost when supplemen-
tation is stopped.
Antiresorptive therapy in hypogonadal men
Statements
• We recommend antiresorptive treatment in hypogonadal
men at high fracture risk (see also our practical proposal in
our clinical vignettes). 1|⊕⊕⊕○
Evidence
Antiresorptive therapy (bisphosphonates as well as deno-
sumab) has not been evaluated in a selected population of
hypogonadal patients as randomized controlled trials were
performed in osteoporotic men, including both eugonadal
and hypogonadal men. Most of the hypogonadal men in
these trials had low or borderline serum testosterone levels
without clear documentation of their gonadal status. An over-
view of the drugs available for treating osteoporosis in men is
given in Table 3.
Antiresorptive treatment increases bone density in osteo-
porotic men, but data on fracture risk are limited (Vescini
et al., 2016). To date, evidence for fracture risk reduction in
men with low bone density is only available for zoledronate
IV. Importantly, in this study hypogonadal subgroup was
included, new osteoporotic fractures were a primary endpoint,
and X-ray assessment of spinal fractures was used (Boonen
et al., 2012).
Table 3 Overview of the available drugs for osteoporosis treatment in men
Drug Dose Men with low
or borderline
T included in
RCTs
Data on
fractures
in men
Side effects Contraindications Refs
Bisphosphonates
Alendronate 10 mg once
daily or 70 mg
once weekly
Oral
Yes No - Osteonecrosis of the jaw
- Atypical femoral fracture
- Gastrointestinal disorders:
reflux, ulcer, diarrhea
- Muscle and joint pain
- Renal insufficiency
(eGFR < 30 mL/min)
- Hypocalcemia
- Gastrointestinal ulcer
Orwoll et al. (2000)
Risedronate 5 mg once daily
or 35 mg once
weekly
Oral
Yes No - Osteonecrosis of the jaw
- Atypical femoral fracture
- Gastrointestinal disorders:
reflux, ulcer, diarrhea
- Muscle and joint pain
- Renal insufficiency
(eGFR < 30 mL/min)
- Hypocalcemia
- Gastrointestinal ulcer
Boonen et al. (2009),
Ringe et al. (2009)
Zoledronic acid 5 mg once yearly
IV
Yes Yes - Osteonecrosis of the jaw
- Atypical femoral fracture
- Fever after infusion
- Muscle and joint pain
- Hypocalcemia if calcium/
vitamin D substitution is
insufficient
- Renal insufficiency
(eGFR < 35 mL/min)
- Dehydration
- Hypocalcemia
Boonen et al. (2011, 2012),
Lyles et al. (2007)
Human monoclonal antibody RANKL
Denosumab 60 mg every
6 months
SC
Yes No - Hypocalcemia if calcium/
vitamin D substitution is
insufficient
- Hypersensitivity reactions
- Atypical femoral fracture
- Osteonecrosis of the jaw
Hypocalcemia Langdahl et al. (2015),
Orwoll et al. (2012)
PTH analog
Teriparatide 20 lg daily
SC
Yes No - Nausea, headache, dizziness,
muscle pain
- Hypercalcemia
- Nephrolithiasis
- Hyperparathyroidism
- Osteosarcoma
- Skeletal metastases
- Paget disease
- Open epiphyses
Kaufman et al. (2005),
Orwoll et al. (2003)
IV, intravenous; SC, subcutaneous administration; eGFR, estimated glomerular filtration rate.
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Remarks
Bisphosphonates increase BMD and improve bone mass in
men with osteoporosis (Orwoll et al., 2000; Boonen et al., 2009;
Ringe et al., 2009).
In addition, there is also evidence that zoledronate reduces
fracture risk as well as mortality in mixed male–female popula-
tion irrespective of bone density (Lyles et al., 2007).
Calcium and vitamin D supplements should always be started
when starting antiresorptive therapy as supplements were used
in all clinical trials.
Hypocalcemia and/or vitamin D deficiency should be cor-
rected before an antiresorptive drug is started.
Impact of testosterone replacement therapy (TRT) on bone
Statements
• We recommend TRT in young adult hypogonadal patients in
order to prevent bone loss and to help acquire peak bone
mass. 1|⊕⊕○○
• For the indication of TRT in other patient groups, we suggest
referring to guidelines on male hypogonadism. The potential
benefit of TRT on BMD and fracture risk will probably depend
on the etiology of hypogonadism, age of onset, duration, and
severity of testosterone deficiency but is not well docu-
mented. 2|⊕⊕○○
• We do not recommend using TRT alone to treat osteoporosis
in hypogonadal men with high fracture risk (in the absence
of documented effect on fracture risks), and we recommend
to add specific antiresorptive drugs to the therapy, even if
these men are receiving adequate TRT. 1|⊕⊕○○
Evidence
In young hypogonadal men (<25 years old), testosterone
replacement therapy may prevent bone loss, reduce markers of
bone resorption, and help to acquire peak bone acquisition
(Laitinen et al., 2012). Furthermore, in young hypogonadal
patients with open epiphyses the effect of testosterone replace-
ment on bone density may be more pronounced.
Besides, in elderly men, the effect of TRT on bone density
seems to depend on the severity of testosterone deficiency. This
was evaluated in a meta-analysis. The effect of TRT was consid-
ered significant at the lumbar spine and when using parenteral
testosterone (Tracz et al., 2006). Furthermore, in a recent ran-
domized controlled trial, testosterone treatment increased BMD
in hypogonadal men. Also in this study, the effect was more pro-
nounced in the spine than in the hip (Snyder et al., 2017).
Importantly, there is no evidence that TRT reduces fracture risk
in older men with normal or borderline low testosterone levels
(Vescini et al., 2016). Additionally, the role of testosterone
replacement on top of antiresorptive treatment in hypogonadal
patients at high risk of fractures is not established.
Antiresorptive therapy in patients receiving ADT
Statements
• We recommend starting antiresorptive treatment in ADT-
treated prostate cancer patients with moderate to high frac-
ture risk (see section on FRAX score). 1|⊕⊕⊕⊕
• We suggest close follow-up of ADT-treated patients with a low
fracture risk. 2|⊕⊕○○
Evidence
Despite their high fracture risk, prostate cancer patients and
hypersexuality patients on ADT remain undertreated for osteo-
porosis. A decrease in BMD is already observed following
6 months of ADT therapy. The longer the duration of ADT, the
higher the fracture risk (Bienz & Saad, 2015).
Benefits of antiresorptive therapy on fracture risk are well
established, and several antiresorptive drugs have been evalu-
ated in these patients. Both bisphosphonates and denosumab
have positive effects on BMD as well as on fracture risk. In most
RCTs, antiresorptive therapy is initiated when ADT is started, to
prevent ADT-related bone loss, also in men without osteoporo-
sis. For some drugs, higher doses were used than in men with
idiopathic osteoporosis. An overview is given in Table 4.
Remarks
Calcium/vitamin D supplementation alone, without an antire-
sorptive agent, is inadequate to prevent ADT-associated bone
loss.
The risk of osteonecrosis of the jaw following antiresorptive
treatment is overall considered very low but may be higher in
the population of oncological patients. Therefore, dental evalua-
tion before initiating therapy is recommended at the start of
treatment.
In men with hormone-sensitive bone metastatic prostate can-
cer, bisphosphonates have not shown to decrease the rate of
skeletal-related events (complications from bone metastases:
pain, functional impairment, pathologic fractures). Denosumab
has not been tested for this indication (Smith et al., 2014).
Monotherapy with the anti-androgen bicalutamide results in a
stable or increased BMD (Smith, 2002; Wadhwa et al., 2009).
These patients are not at risk of developing osteoporosis.
Follow-up
DXA is useful to follow up the efficacy as well as compliance of
antiresorptive treatment. The frequency of DXA follow-up is
however not well defined or established. In patients considered
at low risk at baseline, a 5-year follow-up of bone status should
probably be sufficient. In patients at higher risks, shorter inter-
vals may be needed. In men treated with antiresorptive therapy,
regular measurement of calcium, vitamin D, and kidney function
is recommended.
CONCLUSIONS (SEE KEY MESSAGES)
Within the context of the andrological setting, bone health
should receive full consideration in patients with hypogonadism
and osteoporosis should be ruled out or treated based on
specific partial or complete workup (Box 4 & Fig. 1).
List of all recommendations
• We recommend considering bone health in all andrological
patients with documented hypogonadism at first visit. 1|
⊕⊕○○
• We suggest assessing clinical aspects of bone health as
reported in Table 1. 2|⊕⊕○○
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• We suggest including spine observation and follow-up of
patient’s height in the clinical workup. 2|⊕⊕○○
• We recommend having serum total testosterone measured
twice on a morning blood sample. 1|⊕⊕⊕○
• We recommend measuring again total testosterone and SHBG
if only a single measurement documenting low testosterone is
available. LH and prolactin are useful to better characterize
hypogonadism. 1|⊕⊕⊕○
• We do not recommend routine measurement of serum estra-
diol. 1|⊕⊕○○
• We suggest measuring estradiol only when a validated mass
spectrometry-based method is available and in rare cases in
which severe estrogen deficiency is suspected. 2|⊕⊕○○
• We suggest measuring serum 25(OH) vitamin D at baseline in
all hypogonadal men, independently from their BMD.
2|⊕⊕○○
• We suggest measuring serum calcium (or calcium corrected
for albumin when it is applied—see Appendix 2 for Web
links), phosphorous, and PTH in all hypogonadal patients
with documented low BMD. 2|⊕⊕○○
• We do not recommend the routine use of bone turnover
markers in the management of male or hypogonadal osteo-
porosis. 1|⊕⊕⊕○
Table 4 Overview of antiresorptive drugs in ADT patients
Drug Dose Refs
Zoledronic acid 4 mg IV every 3 months Smith et al. (2003)
Risedronate 35 mg oral weekly Choo et al. (2013)
Pamidronate 60 mg IV every 12 weeks Smith et al. (2001)
Alendronate 70 mg oral weekly Greenspan et al. (2007),
Klotz et al. (2013)
Denosumab 60 mg SC every 6 months Smith et al. (2009)
IV, intravenous; SC, subcutaneous administration.
interview 
See Tables 1 and 2 
for guidance 
Physical 
examination 
See Table 1 for guidance 
Assess 
additional 
risk factors 
for osteoporosis 
Assess 
fracture risk 
FRAX 
with or without 
BMD 
Imaging 
X-ray 
Oriented by interview 
and physical examination 
DXA 
Mandatory in hypogonadal 
 men 
Biochemical 
measurements 
Exclude other forms of secondary 
osteoporosis 
Refer to general guidelines for osteoporosis 
Serum sex steroids, Vitamin D, 
calcium, phosphorous, PTH 
Exclude Vitamin D deficiency and primary 
hyperparathyroidism 
Treatment
Lyfestyle interventions 
Calcium+Vitamin D supplementation 
Testosterone replacement Antiresorptive therapies 
Prevent further bone loss Prevent fractures
Andrological
outpatient clinic
Serum testosterone, SHBG 
to confirm hypogonadism 
(LH and prolactin may be useful) 
Refer to guidelines for male hypogonadism 
Figure 1 Workup for the assessment of bone
health in the andrological outpatient clinic.
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• We recommend BMD measurement by DXA in all hypogo-
nadal patients with documented hypogonadism and/or
serum testosterone <200 ng/dL. 1|⊕⊕⊕○
• We suggest BMD measurement by DXA in all hypogonadal
patients with slightly decreased serum total testosterone (be-
tween 200 and 300 ng/dL), especially in young patients or in
patients with hypogonadal symptoms. 2|⊕⊕○○
• We recommend that all patients who need ADT (for prostate
cancer or hypersexuality) should also be evaluated by DXA.
1|⊕⊕⊕⊕
• We suggest BMD measurement by DXA in men with a well-
documented history of hypogonadism. 2|⊕⊕⊕○
• We recommend X-ray of the dorsolumbar spine when osteo-
porotic fractures are suspected on the basis of patient’s medi-
cal history, physical examination, and/or the presence of
localized bone pain. 1|⊕⊕⊕○
• We recommend using X-ray to confirm the diagnosis of severe
osteoporosis. 1|⊕⊕○○
• We however do not recommend the use of X-ray for the diag-
nosis of osteoporosis or osteopenia. 1|⊕⊕⊕⊕
• We do not recommend the use of other techniques different
than DXA and X-ray for the diagnosis of osteoporosis or
osteopenia and osteoporotic fractures. 1|⊕⊕⊕○
• We suggest calculating the FRAX score in all men with con-
firmed hypogonadism. 2|⊕⊕⊕○
• In general, smoking cessation, a reduction in alcohol intake,
and weight-bearing exercises are recommended. 1|⊕⊕○○
• We suggest introducing lifestyle interventions when hypogo-
nadism is diagnosed or when ADT is started and should be
continued throughout life. 2|⊕⊕○○
• We suggest increasing dietary intake of calcium if the dietary
calcium intake is insufficient. 2|⊕⊕○○
• If dietary calcium intake remains inadequate and/or vita-
min D serum levels are low, we suggest to initiate pharma-
cological supplementation with both calcium and vitamin
D. 2|⊕○○○
• We do not recommend monotherapy with either one of them.
1|⊕⊕○○
• We do not recommend the use of calcium/vitamin D supple-
mentation as the only treatment for hypogonadal osteoporo-
sis or androgen deprivation therapy-associated bone loss.
1|⊕⊕⊕○
• We recommend starting antiresorptive therapy only in combi-
nation with calcium and vitamin D supplementation.
1|⊕⊕○○
• We recommend antiresorptive treatment in hypogonadal
men at high fracture risk (see also our practical proposal in
our clinical vignettes). 1|⊕⊕⊕○
• We recommend TRT in young adult hypogonadal patients in
order to prevent bone loss and to help acquire peak bone
mass. 1|⊕⊕○○
• For the indication of TRT in other patient groups, we suggest
to refer guidelines on male hypogonadism. The potential ben-
efit of TRT on BMD and fracture risk will probably depend on
the etiology of hypogonadism, age of onset, duration, and
severity of testosterone deficiency but is not well docu-
mented. 2|⊕⊕○○
• We do not recommend using TRT alone to treat osteoporosis
in hypogonadal men with high fracture risk (in the absence of
documented effect on fracture risks), and we recommend to
add specific antiresorptive drugs to the therapy, even if these
men are receiving adequate TRT. 1|⊕⊕○○
• We recommend starting antiresorptive treatment in ADT-
treated prostate cancer patients with moderate to high frac-
ture risk (see section on FRAX score). 1|⊕⊕⊕⊕
• We suggest close follow-up of ADT-treated patients with a low
fracture risk. 2|⊕⊕○○
REFERENCES
Aguirre LE, Colleluori G, Fowler KE, Jan IZ, Villareal K, Qualls C, Robbins
D, Villareal DT & Armamento-Villareal R. (2015) High aromatase
activity in hypogonadal men is associated with higher spine bone
mineral density, increased truncal fat and reduced lean mass. Eur J
Endocrinol 173, 167–174.
Almeida M, Laurent MR, Dubois V, Claessens F, O’Brien CA, Bouillon
R, Vanderschueren D & Manolagas SC. (2017) Estrogens and
androgens in skeletal physiology and pathophysiology. Physiol Rev
97, 135–187.
Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, Matsumoto AM,
Bremner WJ & Tenover JL. (2004) Exogenous testosterone or
testosterone with finasteride increases bone mineral density in older
men with low serum testosterone. J Clin Endocrinol Metab 89, 503–
510.
Avenell A, Mak JC & O’Connell D. (2014) Vitamin D and vitamin D
analogues for preventing fractures in post-menopausal women and
older men. Cochrane Database Syst Rev 4, Cd000227.
Basaria S. (2014) Male hypogonadism. Lancet 383, 1250–1263.
Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ,
Swerdloff RS & Montori VM. (2010) Testosterone therapy in men with
androgen deficiency syndromes: an Endocrine Society clinical practice
guideline. J Clin Endocrinol Metab 95, 2536–2559.
Bienz M & Saad F. (2015) Androgen-deprivation therapy and bone
loss in prostate cancer patients: a clinical review. BoneKEy Rep 4, 716.
Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci
C & Potts JT Jr. (2014) Guidelines for the management of
asymptomatic primary hyperparathyroidism: summary statement
from the Fourth International Workshop. J Clin Endocrinol Metab 99,
3561–3569.
Binkley N, Adler R & Bilezikian JP. (2014) Osteoporosis diagnosis in men:
the T-score controversy revisited. Curr Osteoporos Rep 12, 403–409.
Bonomi M, Rochira V, Pasquali D, Balercia G, Jannini EA & Ferlin A
(2016) Klinefelter syndrome (KS): genetics, clinical phenotype and
hypogonadism. J Endocrinol Invest 40, 123–124.
Box 4
Key message.
• Every patient with confirmed or clinical suspicion of hypogo-
nadism in andrological practice should have initial fracture assess-
ment on basis of history and clinical examination on top of gonadal status/
testosterone measurement.
• lf fracture risk is considered low (e.g., young age, no personal, or
familial fracture history): a) follow clinical guidelines of hypogonadism; and
b) if testosterone needed still, consider DXA (as marker of improvement in
bone health).
• If fracture risk is considered high (e.g., old age, personal and/or
familial history of fracture, very low serum testosterone, and/or indication for
androgen deprivation): (a) plan DXA and consider spine X-ray; and (b) man-
age male osteoporosis independently of indication needed for testosterone
replacement.
© 2018 American Society of Andrology and European Academy of Andrology Andrology, 2018, 6, 272–285 281
BONE HEALTH IN ANDROLOGICAL PATIENTS ANDROLOGY
Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R & Delmas PD.
(2009) Once-weekly risedronate in men with osteoporosis: results of a
2-year, placebo-controlled, double-blind, multicenter study. J Bone
Miner Res 24, 719–725.
Boonen S, Orwoll E, Magaziner J, Colon-Emeric CS, Adachi JD, Bucci-
Rechtweg C, Haentjens P, Kaufman JM, Rizzoli R, Vanderschueren D,
Claessens F, Sermon A, Witvrouw R, Milisen K, Su G & Lyles KW.
(2011) Once-yearly zoledronic acid in older men compared with
women with recent hip fracture. J Am Geriatr Soc 59, 2084–2090.
Boonen S, Reginster JY, Kaufman JM, Lippuner K, Zanchetta J, Langdahl
B, Rizzoli R, Lipschitz S, Dimai HP, Witvrouw R, Eriksen E, Brixen K,
Russo L, Claessens F, Papanastasiou P, Antunez O, Su G, Bucci-
Rechtweg C, Hruska J, Incera E, Vanderschueren D & Orwoll E. (2012)
Fracture risk and zoledronic acid therapy in men with osteoporosis. N
Engl J Med 367, 1714–1723.
Bouillon R, Van Schoor NM, Gielen E, Boonen S, Mathieu C,
Vanderschueren D & Lips P. (2013) Optimal vitamin D status: a critical
analysis on the basis of evidence-based medicine. J Clin Endocrinol
Metab 98, E1283–E1304.
Buvat J, Maggi M, Guay A & Torres LO. (2013) Testosterone deficiency in
men: systematic review and standard operating procedures for
diagnosis and treatment. J Sex Med 10, 245–284.
Cawthon PM, Ewing SK, Mackey DC, Fink HA, Cummings SR, Ensrud KE,
Stefanick ML, Bauer DC, Cauley JA & Orwoll ES. (2012) Change in hip
bone mineral density and risk of subsequent fractures in older men. J
Bone Miner Res 27, 2179–2188.
Choo R, Lukka H, Cheung P, Corbett T, Briones-Urbina R, Vieth R,
Ehrlich L, Kiss A & Danjoux C. (2013) Randomized, double-blinded,
placebo-controlled, trial of risedronate for the prevention of bone
mineral density loss in nonmetastatic prostate cancer patients
receiving radiation therapy plus androgen deprivation therapy. Int J
Radiat Oncol Biol Phys 85, 1239–1245.
Compston J, Cooper A, Cooper C, Francis R, Kanis JA, Marsh D, McCloskey
EV, Reid DM, Selby P &Wilkins M. (2009) Guidelines for the diagnosis
andmanagement of osteoporosis in postmenopausal women andmen
from the age of 50 years in the UK.Maturitas 62, 105–108.
Compston J, Bowring C, Cooper A, Cooper C, Davies C, Francis R, Kanis
JA, Marsh D, McCloskey EV, Reid DM & Selby P. (2013) Diagnosis and
management of osteoporosis in postmenopausal women and older
men in the UK: National Osteoporosis Guideline Group (NOGG)
update 2013.Maturitas 75, 392–396.
Corona G, Rastrelli G, Monami M, Saad F, Luconi M, Lucchese M,
Facchiano E, Sforza A, Forti G, Mannucci E & Maggi M. (2013) Body
weight loss reverts obesity-associated hypogonadotropic
hypogonadism: a systematic review and meta-analysis. Eur J
Endocrinol 168, 829–843.
Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S &
Lindsay R. (2014) Clinician’s guide to prevention and treatment of
osteoporosis. Osteoporos Int 25, 2359–2381.
Cummings SR, Cawthon PM, Ensrud KE, Cauley JA, Fink HA & Orwoll ES.
(2006) BMD and risk of hip and nonvertebral fractures in older men: a
prospective study and comparison with older women. J Bone Miner
Res 21, 1550–1556.
Demers LM, Hankinson SE, Haymond S, Key T, Rosner W, Santen RJ,
Stanczyk FZ, Vesper HW & Ziegler RG. (2015) Measuring estrogen
exposure and metabolism: workshop recommendations on clinical
issues. J Clin Endocrinol Metab 100, 2165–2170.
Drake MT, Murad MH, Mauck KF, Lane MA, Undavalli C, Elraiyah T,
Stuart LM, Prasad C, Shahrour A, Mullan RJ, Hazem A, Erwin PJ &
Montori VM. (2012) Clinical review. Risk factors for low bone mass-
related fractures in men: a systematic review and meta-analysis. J Clin
Endocrinol Metab 97, 1861–1870.
Ettinger B, Ensrud KE, Blackwell T, Curtis JR, Lapidus JA & Orwoll ES.
(2013) Performance of FRAX in a cohort of community-dwelling,
ambulatory older men: the Osteoporotic Fractures in Men (MrOS)
study. Osteoporos Int 24, 1185–1193.
Ferlin A, Selice R, Carraro U & Foresta C. (2013) Testicular function and
bone metabolism–beyond testosterone. Nat Rev Endocrinol 9, 548–554.
Fink HA, Ewing SK, Ensrud KE, Barrett-Connor E, Taylor BC, Cauley JA &
Orwoll ES. (2006) Association of testosterone and estradiol deficiency
with osteoporosis and rapid bone loss in older men. J Clin Endocrinol
Metab 91, 3908–3915.
Finkelstein JS, Klibanski A, Neer RM, Greenspan SL, Rosenthal DI &
Crowley WF Jr. (1987) Osteoporosis in men with idiopathic
hypogonadotropic hypogonadism. Ann Intern Med 106, 354–361.
Finkelstein JS, Lee H, Leder BZ, Burnett-Bowie SA, Goldstein DW,
Hahn CW, Hirsch SC, Linker A, Perros N, Servais AB, Taylor AP,
Webb ML, Youngner JM & Yu EW. (2016) Gonadal steroid-
dependent effects on bone turnover and bone mineral density in
men. J Clin Invest 126, 1114–1125.
Gaffney CD, Pagano MJ, Kuker AP, Stember DS & Stahl PJ. (2015)
Osteoporosis and low bone mineral density in men with testosterone
deficiency syndrome. Sex Med Rev 3, 298–315.
Gluszko P, Lorenc RS, Karczmarewicz E, Misiorowski W & Jaworski M.
(2014) Polish guidelines for the diagnosis and management of
osteoporosis: a review of 2013 update. Pol Arch Med Wewn 124, 255–
263.
Green AD, Colon-Emeric CS, Bastian L, Drake MT & Lyles KW. (2004)
Does this woman have osteoporosis? JAMA 292, 2890–2900.
Greenspan SL, Nelson JB, Trump DL & Resnick NM. (2007) Effect of
once-weekly oral alendronate on bone loss in men receiving androgen
deprivation therapy for prostate cancer: a randomized trial. Ann Intern
Med 146, 416–424.
Harvey NC, Johansson H, Oden A, Karlsson MK, Rosengren BE,
Ljunggren O, Cooper C, McCloskey E, Kanis JA, Ohlsson C &
Mellstrom D. (2016) FRAX predicts incident falls in elderly men:
findings from MrOs Sweden. Osteoporos Int 27, 267–274.
Huhtaniemi I. (2014) Late-onset hypogonadism: current concepts and
controversies of pathogenesis, diagnosis and treatment. Asian J Androl
16, 192–202.
de Kam D, Smulders E, Weerdesteyn V & Smits-Engelsman BC. (2009)
Exercise interventions to reduce fall-related fractures and their risk
factors in individuals with low bone density: a systematic review of
randomized controlled trials. Osteoporos Int 20, 2111–2125.
Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC & Khaltaev N.
(1994) The diagnosis of osteoporosis. J Bone Miner Res 9, 1137–1141.
Kanis JA, Johansson H, Johnell O, Oden A, De Laet C, Eisman JA, Pols H &
Tenenhouse A. (2005a) Alcohol intake as a risk factor for fracture.
Osteoporos Int 16, 737–742.
Kanis JA, Johnell O, Oden A, Johansson H, De Laet C, Eisman JA, Fujiwara
S, Kroger H, McCloskey EV, Mellstrom D, Melton LJ, Pols H, Reeve J,
Silman A & Tenenhouse A. (2005b) Smoking and fracture risk: a meta-
analysis. Osteoporos Int 16, 155–162.
Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ 3rd & Khaltaev
N. (2008) A reference standard for the description of osteoporosis.
Bone 42, 467–475.
Kanis JA, Bianchi G, Bilezikian JP, Kaufman JM, Khosla S, Orwoll E &
Seeman E. (2011) Towards a diagnostic and therapeutic consensus in
male osteoporosis. Osteoporos Int 22, 2789–2798.
Kaufman JM, Orwoll E, Goemaere S, San Martin J, Hossain A, Dalsky
GP, Lindsay R & Mitlak BH. (2005) Teriparatide effects on
vertebral fractures and bone mineral density in men with
osteoporosis: treatment and discontinuation of therapy. Osteoporos
Int 16, 510–516.
Khan AA, Hanley DA, Rizzoli R, Bollerslev J, Young JE, Rejnmark L,
Thakker R, D’Amour P, Paul T, Van US, Shrayyef MZ, Goltzman D,
Kaiser S, Cusano NE, Bouillon R, Mosekilde L, Kung AW, Rao SD,
Bhadada SK, Clarke BL, Liu J, Duh Q, Lewiecki EM, Bandeira F, Eastell
282 Andrology, 2018, 6, 272–285 © 2018 American Society of Andrology and European Academy of Andrology
V. Rochira, L. Antonio and D. Vanderschueren ANDROLOGY
R, Marcocci C, Silverberg SJ, Udelsman R, Davison KS, Potts JT Jr,
Brandi ML & Bilezikian JP. (2016) Primary hyperparathyroidism:
review and recommendations on evaluation, diagnosis, and
management. A Canadian and international consensus. Osteoporos Int
28, 1–19.
Khosla S, Melton LJ 3rd, Atkinson EJ, O’Fallon WM, Klee GG & Riggs BL.
(1998) Relationship of serum sex steroid levels and bone turnover
markers with bone mineral density in men and women: a key role for
bioavailable estrogen. J Clin Endocrinol Metab 83, 2266–2274.
Klotz LH, McNeill IY, Kebabdjian M, Zhang L & Chin JL. (2013) A phase 3,
double-blind, randomised, parallel-group, placebo-controlled study of
oral weekly alendronate for the prevention of androgen deprivation
bone loss in nonmetastatic prostate cancer: the Cancer and
Osteoporosis Research with Alendronate and Leuprolide (CORAL)
study. Eur Urol 63, 927–935.
Laitinen EM, Hero M, Vaaralahti K, Tommiska J & Raivio T. (2012)
Bone mineral density, body composition and bone turnover in
patients with congenital hypogonadotropic hypogonadism. Int J
Androl 35, 534–540.
Langdahl BL, Teglbjaerg CS, Ho PR, Chapurlat R, Czerwinski E, Kendler
DL, Reginster JY, Kivitz A, Lewiecki EM, Miller PD, Bolognese MA,
McClung MR, Bone HG, Ljunggren O, Abrahamsen B, Gruntmanis U,
Yang YC, Wagman RB, Mirza F, Siddhanti S & Orwoll E. (2015) A 24-
month study evaluating the efficacy and safety of denosumab for the
treatment of men with low bone mineral density: results from the
ADAMO trial. J Clin Endocrinol Metab 100, 1335–1342.
Lee DM, Tajar A, Pye SR, Boonen S, Vanderschueren D, Bouillon R,
O’Neill TW, Bartfai G, Casanueva FF, Finn JD, Forti G, Giwercman A,
Han TS, Huhtaniemi IT, Kula K, Lean ME, Pendleton N, Punab M &
Wu FC. (2012) Association of hypogonadism with vitamin D status: the
European Male Ageing Study. Eur J Endocrinol 166, 77–85.
Lewiecki EM. (2013) Imaging technologies for assessment of skeletal
health in men. Curr Osteoporos Rep 11, 1–10.
Lewiecki EM. (2015) Osteoporosis: clinical evaluation. In: LJ De Groot, G
Chrousos, K Dungan, et al., editors. Endotext [Internet]. MDText.com
Inc, South Dartmouth, MA. Available from: https://www.ncbi.nlm.nih.
gov/books/NBK279049/.
Lewis CE, Ewing SK, Taylor BC, Shikany JM, Fink HA, Ensrud KE, Barrett-
Connor E, Cummings SR & Orwoll E. (2007) Predictors of non-spine
fracture in elderly men: the MrOS study. J Bone Miner Res 22, 211–219.
Lim LS, Hoeksema LJ & Sherin K. (2009) Screening for osteoporosis in the
adult U.S. population: ACPM position statement on preventive
practice. Am J Prev Med 36, 366–375.
Lunenfeld B, Mskhalaya G, Zitzmann M, Arver S, Kalinchenko S, Tishova Y
& Morgentaler A. (2015) Recommendations on the diagnosis, treatment
and monitoring of hypogonadism in men. Aging Male 18, 5–15.
Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF,
Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA,
Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ,
Horowitz Z, Eriksen EF & Boonen S. (2007) Zoledronic acid in reducing
clinical fracture and mortality after hip fracture. N Engl J Med 357,
nihpa40967.
Madeo B, Zirilli L, Caffagni G, Diazzi C, Sanguanini A, Pignatti E, Carani
C & Rochira V. (2007) The osteoporotic male: overlooked and
undermanaged? Clin Interv Aging 2, 305–312.
Makras P, Vaiopoulos G & Lyritis GP. (2012) 2011 guidelines for the
diagnosis and treatment of osteoporosis in Greece. J Musculoskelet
Neuronal Interact 12, 38–42.
Marcocci C & Cetani F. (2011) Clinical practice. Primary
hyperparathyroidism. N Engl J Med 365, 2389–2397.
Moyer VA. (2013) Vitamin D and calcium supplementation to prevent
fractures in adults: U.S. Preventive Services Task Force
recommendation statement. Ann Intern Med 158, 691–696.
Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S,
Weber K, Lorenc R, Pietschmann P, Vandormael K & Lombardi A.
(2000) Alendronate for the treatment of osteoporosis in men. N Engl J
Med 343, 604–610.
Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A,
Kaufman JM, Clancy AD & Gaich GA. (2003) The effect of teriparatide
[human parathyroid hormone (1-34)] therapy on bone density in men
with osteoporosis. J Bone Miner Res 18, 9–17.
Orwoll E, Teglbjaerg CS, Langdahl BL, Chapurlat R, Czerwinski E, Kendler
DL, Reginster JY, Kivitz A, Lewiecki EM, Miller PD, Bolognese MA,
McClung MR, Bone HG, Ljunggren O, Abrahamsen B, Gruntmanis U,
Yang YC, Wagman RB, Siddhanti S, Grauer A, Hall JW & Boonen S.
(2012) A randomized, placebo-controlled study of the effects of
denosumab for the treatment of men with low bone mineral density. J
Clin Endocrinol Metab 97, 3161–3169.
Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S,
Hanley DA, Hodsman A, Jamal SA, Kaiser SM, Kvern B, Siminoski K &
Leslie WD. (2010) 2010 clinical practice guidelines for the diagnosis
and management of osteoporosis in Canada: summary. CMAJ 182,
1864–1873.
Pasco JA, Lane SE, Brennan SL, Timney EN, Bucki-Smith G, Dobbins AG,
Nicholson GC & Kotowicz MA. (2014) Fracture risk among older men:
osteopenia and osteoporosis defined using cut-points derived from
female versus male reference data. Osteoporos Int 25, 857–862.
Pye SR, Devakumar V, Boonen S, Borghs H, Vanderschueren D, Adams
JE, Ward KA, Bartfai G, Casanueva FF, Finn JD, Forti G, Giwercman A,
Han TS, Huhtaniemi IT, Kula K, Lean ME, Pendleton N, Punab M,
Silman AJ, Wu FC & O’Neill TW. (2010) Influence of lifestyle factors on
quantitative heel ultrasound measurements in middle-aged and
elderly men. Calcif Tissue Int 86, 211–219.
Qaseem A, Forciea MA, McLean RM & Denberg TD. (2017) Treatment of
low bone density or osteoporosis to prevent fractures in men and
women: a clinical practice guideline update from the American college
of physicians. Ann Intern Med 166, 818.
Reid IR, Bolland MJ & Grey A. (2014) Effects of vitamin D supplements on
bone mineral density: a systematic review and meta-analysis. Lancet
383, 146–155.
Ringe JD, Farahmand P, Faber H & Dorst A. (2009) Sustained efficacy of
risedronate in men with primary and secondary osteoporosis: results
of a 2-year study. Rheumatol Int 29, 311–315.
Rochira V & Carani C. (2009) Aromatase deficiency in men: a clinical
perspective. Nat Rev Endocrinol 5, 559–568.
Rochira V & Carani C. (2017) Estrogen deficiency in men. In:
Endocrinology of the Testis and Male Reproduction (eds M Simoni & I
Huhtaniemi), pp. 1–32. Springer International Publishing, Cham.
Rochira V, Madeo B, Zirilli L, Granata AR & Carani C. (2006) Osteoporosis
and male age-related hypogonadism: role of sex steroids on bone
(patho)physiology. Eur J Endocrinol 154, 175–185.
Rochira V, Kara E & Carani C. (2015) The endocrine role of estrogens on
human male skeleton. Int J Endocrinol 2015, 165215.
Rochira VMB, Diazzi C, Zirilli L, Santi D & Carani C. (2016) Estrogens and
male reproduction. In: LJ De Groot, G Chrousos, K Dungan, et al.,
editors. Endotext [Internet]. MDText.com Inc, South Dartmouth, MA.
Available from: https://www.ncbi.nlm.nih.gov/books/NBK278933/.
Rosner W, Auchus RJ, Azziz R, Sluss PM & Raff H. (2007) Position statement:
utility, limitations, and pitfalls in measuring testosterone: an Endocrine
Society position statement. J Clin Endocrinol Metab 92, 405–413.
Rosner W, Hankinson SE, Sluss PM, Vesper HW & Wierman ME. (2013)
Challenges to the measurement of estradiol: an endocrine society
position statement. J Clin Endocrinol Metab 98, 1376–1387.
Rossini M, Adami S, Bertoldo F, Diacinti D, Gatti D, Giannini S, Giusti A,
Malavolta N, Minisola S, Osella G, Pedrazzoni M, Sinigaglia L,
Viapiana O & Isaia GC. (2016) Guidelines for the diagnosis, prevention
and management of osteoporosis. Reumatismo 68, 1–39.
Shahinian VB, Kuo YF, Freeman JL & Goodwin JS. (2005) Risk of fracture
after androgen deprivation for prostate cancer. N Engl J Med 352, 154–
164.
© 2018 American Society of Andrology and European Academy of Andrology Andrology, 2018, 6, 272–285 283
BONE HEALTH IN ANDROLOGICAL PATIENTS ANDROLOGY
Simoni MFF, Roli L & Pagotto U. (2012) Methodology for measuring
testosterone, dihydrotestosterone and sex hormone-binding globulin
in a clinical setting. In: Testosterone Action, Deficiency, Substitution
(eds ENHM Behre), pp. 60–86. Cambridge University Press,
Cambridge, UK.
Siris ES, Adler R, Bilezikian J, Bolognese M, Dawson-Hughes B, Favus MJ,
Harris ST, Jan de Beur SM, Khosla S, Lane NE, Lindsay R, Nana AD,
Orwoll ES, Saag K, Silverman S & Watts NB. (2014) The clinical
diagnosis of osteoporosis: a position statement from the National
Bone Health Alliance Working Group. Osteoporos Int 25, 1439–1443.
Smith MR. (2002) Osteoporosis and other adverse body composition
changes during androgen deprivation therapy for prostate cancer.
Cancer Metastasis Rev 21, 159–166.
Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld
DA, Kantoff PW & Finkelstein JS. (2001) Pamidronate to prevent bone
loss during androgen-deprivation therapy for prostate cancer. N Engl J
Med 345, 948–955.
Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S & Zinner
N. (2003) Randomized controlled trial of zoledronic acid to prevent
bone loss in men receiving androgen deprivation therapy for
nonmetastatic prostate cancer. J Urol 169, 2008–2012.
Smith MR, Egerdie B, Hernandez Toriz N, Feldman R, Tammela TL, Saad
F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ & Goessl C.
(2009) Denosumab in men receiving androgen-deprivation therapy for
prostate cancer. N Engl J Med 361, 745–755.
Smith MR, Halabi S, Ryan CJ, Hussain A, Vogelzang N, Stadler W, Hauke
RJ, Monk JP, Saylor P, Bhoopalam N, Saad F, Sanford B, Kelly WK,
Morris M & Small EJ. (2014) Randomized controlled trial of early
zoledronic acid in men with castration-sensitive prostate cancer and
bone metastases: results of CALGB 90202 (alliance). J Clin Oncol 32,
1143–1150.
Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH,
Dlewati A, Staley J, Santanna J, Kapoor SC, Attie MF, Haddad JG
Jr & Strom BL. (1999) Effect of testosterone treatment on bone
mineral density in men over 65 years of age. J Clin Endocrinol
Metab 84, 1966–1972.
Snyder PJ, Kopperdahl DL, Stephens-Shields AJ, Ellenberg SS, Cauley JA,
Ensrud KE, Lewis CE, Barrett-Connor E, Schwartz AV, Lee DC, Bhasin
S, Cunningham GR, Gill TM, Matsumoto AM, Swerdloff RS, Basaria S,
Diem SJ, Wang C, Hou X, Cifelli D, Dougar D, Zeldow B, Bauer DC &
Keaveny TM. (2017) Effect of testosterone treatment on volumetric
bone density and strength in older men with low testosterone: a
controlled clinical trial. JAMA Intern Med 177, 471–479.
Soen S, Fukunaga M, Sugimoto T, Sone T, Fujiwara S, Endo N, Gorai I,
Shiraki M, Hagino H, Hosoi T, Ohta H, Yoneda T & Tomomitsu T.
(2013) Diagnostic criteria for primary osteoporosis: year 2012 revision.
J Bone Miner Metab 31, 247–257.
Soyka LA, Fairfield WP & Klibanski A. (2000) Clinical review 117:
hormonal determinants and disorders of peak bone mass in children. J
Clin Endocrinol Metab 85, 3951–3963.
Stepan JJ, LachmanM, Zverina J, Pacovsky V & Baylink DJ. (1989) Castrated
men exhibit bone loss: effect of calcitonin treatment on biochemical
indices of bone remodeling. J Clin Endocrinol Metab 69, 523–527.
Swanson CM, Nielson CM, Shrestha S, Lee CG, Barrett-Connor E, Jans I,
Cauley JA, Boonen S, Bouillon R, Vanderschueren D & Orwoll ES.
(2014) Higher 25(OH)D2 is associated with lower 25(OH)D3 and 1,25
(OH)2D3. J Clin Endocrinol Metab 99, 2736–2744.
Swiglo BA, Murad MH, Schunemann HJ, Kunz R, Vigersky RA, Guyatt GH
& Montori VM. (2008) A case for clarity, consistency, and helpfulness:
state-of-the-art clinical practice guidelines in endocrinology using the
grading of recommendations, assessment, development, and
evaluation system. J Clin Endocrinol Metab 93, 666–673.
Tajar A, Huhtaniemi IT, O’Neill TW, Finn JD, Pye SR, Lee DM, Bartfai G,
Boonen S, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K,
Labrie F, Lean ME, Pendleton N, Punab M, Vanderschueren D & Wu
FC. (2012) Characteristics of androgen deficiency in late-onset
hypogonadism: results from the European Male Aging Study (EMAS). J
Clin Endocrinol Metab 97, 1508–1516.
Tracz MJ, Sideras K, Bolona ER, Haddad RM, Kennedy CC, Uraga MV,
Caples SM, Erwin PJ & Montori VM. (2006) Testosterone use in men
and its effects on bone health. A systematic review and meta-analysis
of randomized placebo-controlled trials. J Clin Endocrinol Metab 91,
2011–2016.
U.S.-Preventive-Services-Task-Force. (2011) Screening for osteoporosis:
U.S. preventive services task force recommendation statement. Ann
Intern Med 154, 356–364.
Vasikaran SD & Chubb SA. (2016) The use of biochemical markers of
bone turnover in the clinical management of primary and secondary
osteoporosis. Endocrine 52, 222–225.
Vermeulen A, Verdonck L & Kaufman JM. (1999) A critical evaluation of
simple methods for the estimation of free testosterone in serum. J Clin
Endocrinol Metab 84, 3666–3672.
Vescini F, Attanasio R, Balestrieri A, Bandeira F, Bonadonna S, Camozzi
V, Cassibba S, Cesareo R, Chiodini I, Francucci CM, Gianotti L,
Grimaldi F, Guglielmi R, Madeo B, Marcocci C, Palermo A, Scillitani A,
Vignali E, Rochira V & Zini M. (2016) Italian association of clinical
endocrinologists (AME) position statement: drug therapy of
osteoporosis. J Endocrinol Invest 39, 807–834.
Wadhwa VK, Weston R, Mistry R & Parr NJ. (2009) Long-term changes in
bone mineral density and predicted fracture risk in patients
receiving androgen-deprivation therapy for prostate cancer, with
stratification of treatment based on presenting values. BJU Int 104,
800–805.
Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ,
Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman
C, Thompson IM, Weidner W & Wu FC. (2009) Investigation,
treatment, and monitoring of late-onset hypogonadism in males: ISA,
ISSAM, EAU, EAA, and ASA recommendations. J Androl 30, 1–9.
Wang A, Obertova Z, Brown C, Karunasinghe N, Bishop K, Ferguson L &
Lawrenson R. (2015) Risk of fracture in men with prostate cancer on
androgen deprivation therapy: a population-based cohort study in
New Zealand. BMC Cancer 15, 837.
Watts NB, Adler RA, Bilezikian JP, Drake MT, Eastell R, Orwoll ES &
Finkelstein JS. (2012) Osteoporosis in men: an Endocrine Society
clinical practice guideline. J Clin Endocrinol Metab 97, 1802–1822.
Watts NB, Leslie WD, Foldes AJ & Miller PD. (2013) 2013 International
Society for Clinical Densitometry Position Development Conference:
Task Force on Normative Databases. J Clin Densitom 16, 472–481.
Willson T, Nelson SD, Newbold J, Nelson RE & LaFleur J. (2015) The
clinical epidemiology of male osteoporosis: a review of the recent
literature. Clin Epidemiol 7, 65–76.
Wu CT, Yang YH, Chen PC, Chen MF & Chen WC. (2015) Androgen
deprivation increases the risk of fracture in prostate cancer patients: a
population-based study in Chinese patients. Osteoporos Int 26, 2281–
2290.
Yang L, Burton AC, Bradburn M, Nielson CM, Orwoll ES & Eastell R.
(2012) Distribution of bone density in the proximal femur and its
association with hip fracture risk in older men: the osteoporotic
fractures in men (MrOS) study. J Bone Miner Res 27, 2314–2324.
284 Andrology, 2018, 6, 272–285 © 2018 American Society of Andrology and European Academy of Andrology
V. Rochira, L. Antonio and D. Vanderschueren ANDROLOGY
APPENDIX 1
List of available guidelines on the management of bone loss in men published in the last 10 years
Male Osteoporosis Guidelines Year Refs
Specific for male osteoporosis
The Endocrine Society Guidelines 2012 Watts et al. (2012)
Toward a diagnostic and therapeutic consensus in male osteoporosis 2011 Kanis et al. (2011)
Advice in Generic (mainly female) Guidelines of Osteoporosis
Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice
Guideline Update from the American College of Physicians
2017 Qaseem et al. (2017)
Italian Society of Osteoporosis, Mineral Metabolism, and Bone Diseases 2016 Rossini et al. (2016)
(UK guidelines for postmenopausal osteoporosis and older men) 2013 Compston et al. (2013)
Japanese Society for Bone and Mineral Research 2013 Soen et al. (2013)
Polish guidelines for the diagnosis and management of osteoporosis: a review of 2013 update 2013 Gluszko et al. (2014)
2011 Guidelines for the Diagnosis and Treatment of Osteoporosis in Greece 2011 Makras et al. (2012)
Canadian Guidelines for Osteoporosis 2010 Papaioannou et al. (2010)
Australian guidelines for postmenopausal osteoporosis and older men 2010 https://www.anzbms.org.au/downloads/
racgp_osteo_guideline.pdf
Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the
age of 50 years in the UK (on behalf of the National Osteoporosis Guideline Group)
2009 Compston et al. (2009)
Advice in Generic (mainly female) Position Statements
Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis. 2016 Vescini et al. (2016)
The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working
Group
2014 Siris et al. (2014)
Clinician’s Guide to Prevention and Treatment of Osteoporosis (provided by expert committee of the National
Osteoporosis Foundation)
2014 Cosman et al. (2014)
Vitamin D and Calcium Supplementation to Prevent Fractures in Adults: U.S. Preventive Services Task Force
Recommendation Statement
2013 Moyer (2013)
Screening for Osteoporosis: U.S. Preventive Services Task Force Recommendation Statement (provided by the
U.S. Preventive Services Task Force)
2011 U.S.-Preventive-Services-Task-Force,
(2011)
Screening for Osteoporosis in the Adult U.S. Population ACPM Position Statement on Preventive Practice 2009 Lim et al. (2009)
APPENDIX 2
Useful online resources for the management of bone loss and osteoporosis in men
Resource name Utility Website (URL)
Free testosterone calculator Calculation of free serum testosterone http://www.issam.ch/freetesto.htm
Serum corrected calcium Calcium correction for albumin https://www.mdcalc.com/calcium-correction-hypoalbuminemia
Genant classification Vertebral fractures classification https://www.iofbonehealth.org/radiological-assessment-and-bone-turnover-
markers
The Fracture Risk Assessment Tool (FRAX) Fracture risk measurement https://www.shef.ac.uk/FRAX/tool.jsp?lang=en
Dietary calcium Esteem of dietary calcium intake http://www.osteoporosis.ca/osteoporosis-canada-calcium-calculator/
eGFR calculator Esteem of glomerular filtration rate http://egfrcalc.renal.org
© 2018 American Society of Andrology and European Academy of Andrology Andrology, 2018, 6, 272–285 285
BONE HEALTH IN ANDROLOGICAL PATIENTS ANDROLOGY
